Related Experiment Video
Updated: May 1, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Exploring the Potential of Natural Products as FoxO1 Inhibitors: an In Silico Approach
Anugya Gupta1, Rajesh Haldhar2, Vipul Agarwal3
1Faculty of Medical and Paramedical Sciences, Madhyanchal Professional University, Bhopal 462044, Madhya Pradesh, India.
Abstract:
FoxO1, a member of the Forkhead transcription factor family subgroup O (FoxO), is expressed in a range of cell types and is crucial for various pathophysiological processes, such as apoptosis and inflammation. While FoxO1's roles in multiple diseases have been recognized, the target has remained largely unexplored due to the absence of cost-effective and efficient inhibitors. Therefore, there is a need for natural FoxO1 inhibitors with minimal adverse effects. In this study, docking, MMGBSA, and ADMET analyses were performed to identify natural compounds that exhibit strong binding affinity to FoxO1. The top candidates were then subjected to molecular dynamics (MD) simulations. A natural product library was screened for interaction with FoxO1 (PDB ID- 3CO6) using the Glide module of the Schrödinger suite. In silico ADMET profiling was conducted using SwissADME and pkCSM web servers. Binding free energies of the selected compounds were assessed with the Prime-MMGBSA module, while the dynamics of the top hits were analyzed using the Desmond module of the Schrödinger suite. Several natural products demonstrated high docking scores with FoxO1, indicating their potential as FoxO1 inhibitors. Specifically, the docking scores of neochlorogenic acid and fraxin were both below -6.0. These compounds also exhibit favorable drug-like properties, and a 25 ns MD study revealed a stable interaction between fraxin and FoxO1. Our findings highlight the potential of various natural products, particularly fraxin, as effective FoxO1 inhibitors with strong binding affinity, dynamic stability, and suitable ADMET profiles.
Insights
Natural compounds like fraxin show promise as FoxO1 inhibitors. Computational studies identified fraxin with strong binding affinity and stable interactions, suggesting potential for new therapeutic strategies against diseases involving FoxO1.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Chemistry
Background:
- Forkhead box protein O1 (FoxO1) is vital in cellular processes like apoptosis and inflammation.
- Existing FoxO1 inhibitors are limited, necessitating the search for natural alternatives with fewer side effects.
Purpose of the Study:
- To identify natural compounds with potent FoxO1 inhibitory activity using computational methods.
- To evaluate the binding affinity, drug-like properties, and dynamic stability of potential natural FoxO1 inhibitors.
Main Methods:
- Screening of a natural product library against FoxO1 (PDB ID: 3CO6) using molecular docking (Schrödinger Glide).
- In silico ADMET profiling using SwissADME and pkCSM.
- Binding free energy calculations (Prime-MMGBSA) and molecular dynamics simulations (Desmond).
Main Results:
- Several natural products exhibited high docking scores, with neochlorogenic acid and fraxin showing scores below -6.0.
- Fraxin demonstrated favorable drug-like properties and stable interactions with FoxO1 during a 25 ns molecular dynamics simulation.
- Identified natural compounds possess strong binding affinity and dynamic stability against FoxO1.
Conclusions:
- Natural products, especially fraxin, are promising candidates for developing novel FoxO1 inhibitors.
- Fraxin's potent inhibitory potential, stability, and favorable ADMET profile warrant further investigation for therapeutic applications.
More Related Videos
00:12A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
Published on: September 22, 2019
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets